← back to search

Shanqing Li

Guangzhou Medical University · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Lung cancer and Cancer, with related work in Stage (stratigraphy), China, Thoracoscopy. Notable publications include 'Cancer situation in China: an analysis based on the global epidemiological data released in 2024', 'Physical activity and cancer risk: a dose‐response analysis for the Global Burden of Disease Study 2019', and 'Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer'.
h-index
citations
352
works
11
NIH funding
primary concept
email

Recent publications

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer
Journal of Clinical Oncology 2025cited by 49position: middledoi
Cancer situation in China: an analysis based on the global epidemiological data released in 2024
Cancer Communications 2024cited by 106position: middledoi
Physical activity and cancer risk: a dose‐response analysis for the Global Burden of Disease Study 2019
Cancer Communications 2023cited by 68position: middledoi
Expert consensus on indocyanine green fluorescence imaging for thoracoscopic lung resection (The Version 2022)
Translational Lung Cancer Research 2022cited by 28position: middledoi
International expert consensus on immunotherapy for early-stage non-small cell lung cancer
Translational Lung Cancer Research 2022cited by 25position: middledoi
DNA methylation patterns at and beyond the histological margin of early-stage invasive lung adenocarcinoma radiologically manifested as pure ground-glass opacity
Clinical Epigenetics 2021cited by 9position: middledoi
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
Journal of Clinical Oncology 2021cited by 8position: middledoi
366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC
Regular and Young Investigator Award Abstracts 2020cited by 1position: middledoi
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Translational Lung Cancer Research 2019cited by 31position: middledoi
The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer
Journal of Thoracic Disease 2018cited by 27position: middledoi
[Clinical pathway of primary lung cancer suegery (2013 edition)].
PubMed 2013cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xiayao Diao · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2023–2024)Jianrong Guo · Sun Yat-sen University2 papers (2023–2024)Chao Guo · Nantong University2 papers (2021–2024)Haibo Qiu · Sun Yat-sen University2 papers (2023–2024)Naikang Zhou · State Power Investment Corporation (China)1 papers (2013–2013) · 1 papers (2013–2013)Lei Yu · The First Affiliated Hospital, Sun Yat-sen University1 papers (2021–2021)Qinghua Zhou · Shanghai Jiao Tong University1 papers (2013–2013)Jianxing He · First Affiliated Hospital of Guangzhou Medical University1 papers (2013–2013)Liang Wang · Shandong University1 papers (2021–2021) · 1 papers (2021–2021)Yueqian Wu · Sun Yat-sen University1 papers (2023–2023)Xiuyi Zhi · Roswell Park Comprehensive Cancer Center1 papers (2013–2013) · 1 papers (2021–2021) · 1 papers (2021–2021)Yiying Liu · South China Agricultural University1 papers (2021–2021) · 1 papers (2013–2013)Yang Song · Shandong University1 papers (2021–2021)Yuan Gao · Soochow University1 papers (2021–2021)Li Mao · Jilin University1 papers (2021–2021)